Breaking News

Global Vaccine Stats – Oxford-Astra zeneca vaccine to be used in India, as per contract, manufacture will also be in India

Global Vaccine Stats - Oxford-Astra zeneca vaccine to be used in India, as per contract, manufacture will also be in India

WORLD NEWS SUPERFAST

INDIA NEWS – According to information received from the Ministry of Health of the World News Superfast, the wait for vaccine in India is nearing its end. So far, there have been 24,35,222 cases of corona virus in India. In which there are 4,75,231 active cases. While 20,96, 04 people have recovered. The death toll has been 53,957. Expectations regarding the vaccine have also increased amidst increasing cases of coronaviruses. According to the World Health Organization (WHO) vaccine tracker, there are now 29 vaccines undergoing human trials. At the same time, 138 vaccines are undergoing pre-clinical testing. China’s state-owned Sinofarm claims that its vaccine will come on the market by December.

Oxford Covid-19 Vaccine

Bharat Biotech-ICMR and Zydus Cadila Vaccine

Indigenous vaccine manufacturers Bharat Biotech-ICMR and Zydus Cadila Vaccine Phase-2 have entered the human trials. At the same time, there are reports that KoviShield made of Oxford-AstraZeneca will be available in India first. Serum Institute of India has obtained permission for Phase-2 and Phase-3 Human Trials in India.

Patent for vaccine made in China by Biosciences

The vaccine produced by Canon Biologics in China has received a patent. The document, published on the website of China’s National Intellectual Property Administration, claimed that the vaccine could be mass-produced in an outbreak. The patent was issued on August 11, according to a report by the Chinese state-run People’s Daily. On the same day, Russian President Vladimir Putin announced the registration of the Russian vaccine “Sputnik-V”.

 The vaccine being developed by the Wuhan Institute of Biological Products of China will be commercially available in December. The head of Sinopharm, the company making it, said that phase-3 trials of the vaccine are moving in the right direction. Sinopharm vaccine will come to 1,000 yuan i.e. about 10,800 rupees. It is of two doses. Which will be given in a gap of 28 days. One dose of this gives protection up to 97% against the corona, while protection is 100% when the second dose is applied.

According to WHO’s tracker, work is going on fast

This vaccine from Sinopharm has been successful in Phase-1/2 trials. Its phase-3 trials are going on. Tests so far have shown that strong antibody response has been found after applying the vaccine. India has completed Biotech Kovacine and Zydus Cadila Vaccine Phase-1. Its phase-2 human trials have started. According to the WHO tracker, work is going on at a fast pace. But the vaccine will come in the market only next year.

The Serum Institute of India has obtained permission for the Phase-2 and Phase-3 trials of the CoveyShield vaccine of Oxford-AstraZeneca in India. For this, hospitals have appealed to Volunteers to come forward. Its Phase-3 has already started in the UK, US and Brazil. That is, even if we do not get the results of trials, the Serum Institute will start making it. This vaccine will be available in India for Rs 225.

WHO - Offical Meeting For Corona Virus

WHO Launches Kovacs Global Vaccine Facility Program

The WHO has designed to raise funds from rich countries and non-profits. So that two billion effective vaccines can be delivered, supporting the worldwide vaccine development program. The deadline of 31 August has been set to join this program.

The Gavi Vaccine Alliance and the Coalition for Epidemic Preparedness Innovations along with WHO are also associated with this program

Kovacs is part of a larger program, called the Access to Kovid-19 Tools (ACT) accelerator. It ensures vaccines, treatment, diagnostic tests and other healthcare resources to fight epidemics. The United States, the UK, Japan and the European Union have spent billions of dollars dealing with vaccine manufacturers. The United States alone has developed $ 11 billion in deals to develop and deliver the vaccine.

Source link